Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itruvone - VistaGen Therapeutics

Drug Profile

Itruvone - VistaGen Therapeutics

Alternative Names: PH 10 - Pherin Pharmaceuticals; PH 10A; PH10 NS

Latest Information Update: 14 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pherin Pharmaceuticals
  • Class Antidepressants; Small molecules; Steroids
  • Mechanism of Action Chemoreceptor cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 14 Nov 2023 Itruvone is still in phase-I trials for Major depressive disorder (In volunteers) in USA (Intranasal)
  • 09 Nov 2023 VistaGen Therapeutics plans a phase IIb trial in Major depressive disorder in USA (Intranasal) in the second half of 2024
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in USA (Intranasal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top